2. 疾患領域
  3. Neurological, Eye or Ear Disease
  4. Depression
  5. P7C3-A20

P7C3-A20 is a derivative of P7C3 with potent proneurogenic and neuroprotective activity. P7C3-A20 exerts an antidepressant-like effect. P7C3-A20 can cross the blood-brain barrier and therefore has the potential for brain injury treatment.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 1235481-90-9

容量 価格（税別） 在庫状況 数量
>無料サンプル (0.1 - 0.2 mg)   今すぐ申し込む  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 74 在庫あり
Solution
10 mM * 1 mL in DMSO USD 74 在庫あり
Solid
5 mg $66 在庫あり
10 mg $99 在庫あり
25 mg $125 在庫あり
50 mg $209 在庫あり
100 mg $319 在庫あり
200 mg   お問い合わせ  
500 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 6 publication(s) in Google Scholar

Other Forms of P7C3-A20:

P7C3-A20 関連抗体

Top Publications Citing Use of Products

    P7C3-A20 purchased from MedChemExpress. Usage Cited in: Neuroscience. 2020 Aug 10;441:197-208.  [Abstract]

    P7C3-A20 alleviates HI injury. MAP-2 and MBP protein levels 7 days after HI in sham, HIE, and HIE + P7C3-A20 5 and 10 mg/kg groups.

    • 生物活性

    • 純度とドキュメンテーション

    • 参考文献

    • カスタマーレビュー

    製品説明

    P7C3-A20 is a derivative of P7C3 with potent proneurogenic and neuroprotective activity. P7C3-A20 exerts an antidepressant-like effect. P7C3-A20 can cross the blood-brain barrier and therefore has the potential for brain injury treatment[1][2][3].

    体外実験

    P7C3-A20 (10-100 μM; 8 hours; PC12 cells) treatment alleviates oxygen-glucose deprivation (OGD)-induced cytotoxicity in PC12 cells[1].
    ? P7C3-A20 (40-100 μM; 8 hours; PC12 cells) treatment alleviates OGD-induced apoptosis in PC12 cells[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    P7C3-A20 関連抗体

    Cell Viability Assay[1]

    Cell Line: PC12 cells
    Concentration: 10 μM, 20 μM, 40 μM, 60 μM, 80 μM, 100 μM
    Incubation Time: 8 hours
    Result: Alleviated oxygen-glucose deprivation (OGD)-induced cytotoxicity in PC12 cells.

    Apoptosis Analysis[1]

    Cell Line: PC12 cells
    Concentration: 40 μM, 60 μM, 80 μM, 100 μM
    Incubation Time: 8 hours
    Result: Alleviated oxygen-glucose deprivation (OGD)-induced apoptosis in PC12 cells.
    体内実験

    P7C3-A20 (5-10?mg/kg; intraperitoneal injection; daily; for 7 days; Sprague-Dawley rats) treatment reduces infarct volume; reverses cell loss in the cortex and hippocampus and improves motor function without causing neurotoxicity in HI model rats. P7C3-A20 prevents HI-induced neuronal injury via activation of the PI3K/AKT/GSK3β signaling pathway[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Sprague-Dawley rats (200-250 g) induced hypoxic-ischemic (HI) injury [1]
    Dosage: 5 mg/kg, 10 mg/kg
    Administration: Intraperitoneal injection; daily; for 7 days
    Result: Reduced infarct volume; reversed cell loss in the cortex and hippocampus and improved motor function without causing neurotoxicity.
    分子量

    506.21

    分子式

    C22H19Br2FN2O
    CAS 番号
    Appearance

    Solid

    Color

    White to yellow

    SMILES

    FC(CNC1=CC(OC)=CC=C1)CN2C3=CC=C(Br)C=C3C4=CC(Br)=CC=C24
    輸送条件

    Room temperature in continental US; may vary elsewhere.
    保管条件
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    溶剤 & 溶解度
    体外: 

    DMSO : ≥ 100 mg/mL (197.55 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.9755 mL 9.8773 mL 19.7546 mL
    5 mM 0.3951 mL 1.9755 mL 3.9509 mL
    10 mM 0.1975 mL 0.9877 mL 1.9755 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始）

    C1

    ×
    体積 （開始）

    V1

    =
    濃度 （終了）

    C2

    ×
    体積 （終了）

    V2

    体内:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 3.85 mg/mL (7.61 mM); Clear solution

      This protocol yields a clear solution of ≥ 3.85 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (38.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.5 mg/mL (4.94 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    純度とドキュメンテーション

    純度: 99.32%

    COA (247 KB)

    取扱説明書 (2659 KB)
    参考文献

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.9755 mL 9.8773 mL 19.7546 mL 49.3866 mL
    5 mM 0.3951 mL 1.9755 mL 3.9509 mL 9.8773 mL
    10 mM 0.1975 mL 0.9877 mL 1.9755 mL 4.9387 mL
    15 mM 0.1317 mL 0.6585 mL 1.3170 mL 3.2924 mL
    20 mM 0.0988 mL 0.4939 mL 0.9877 mL 2.4693 mL
    25 mM 0.0790 mL 0.3951 mL 0.7902 mL 1.9755 mL
    30 mM 0.0658 mL 0.3292 mL 0.6585 mL 1.6462 mL
    40 mM 0.0494 mL 0.2469 mL 0.4939 mL 1.2347 mL
    50 mM 0.0395 mL 0.1975 mL 0.3951 mL 0.9877 mL
    60 mM 0.0329 mL 0.1646 mL 0.3292 mL 0.8231 mL
    80 mM 0.0247 mL 0.1235 mL 0.2469 mL 0.6173 mL
    100 mM 0.0198 mL 0.0988 mL 0.1975 mL 0.4939 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    P7C3-A20 Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質量   濃度   体積   分子量 *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    P7C3-A201235481-90-9OthersHypoxic-ischemicneuroprotectiveinfarctPI3KAKTGSK3βBBBantidepressantInhibitorinhibitorinhibit

    最近チェックした製品:

    オンラインお問い合わせ

    Your information is safe with us. * Required Fields.

    製品名

    		  

    カスタマ需要量 *

    お名前 *

    		 

    タイトル

    メールアドレス *

    		 

    電話番号 *

    デパートメント

    		 

    組纖名 *

    市区町村

    都道府県

    国或いは地域 *

    		      

    必ず会社名を記載ください。個人への返信は行いません。

    備考

    バルクお問い合わせ

    Inquiry Information

    製品名:
    P7C3-A20
    製品番号:
    HY-15978
    数量:
    MCE 日本正規代理店:

    カスタマーレビュー

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    製品名

    		  

    Lot #

    お名前 *

    		 

    メールアドレス *

    電話番号 *

    		 

    部門 *

    組纖名 *

    		 

    国或いは地域 *

    備考

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.